| Filed On | Filing |
|---|---|
| 16 Nov 2026 | Form 4 |
| 16 Nov 2026 |
8-K: Regulation FD Disclosure
________________________________________________________________________________________________________________________ |
| 12 Nov 2026 | 144 |
| 12 Nov 2026 |
Form 4: Daly Richard J, Director
Bought 28,025 shares ($99.3K) |
| 12 Nov 2026 |
Form 4: Davis Matthew W., Chief Development Officer
Gave up 5,303 shares to cover exercise price or tax ($18.7K) |
| 10 Nov 2026 |
Form 4: Daly Richard J, Director
Granted 57,000 Non-Qualified Stock Option (right to buy) |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Pri... |
| 03 Nov 2026 | 10-Q |
| 03 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Warren, N.J., November 3, 2026 – Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, t... |
| 23 Oct 2026 |
Form 4: Cochran John, Director
Acquired 62,229 shares (Other Transaction) |
| 19 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
150023820.2 AMENDED AND RESTATED BYLAWS OF AQUESTIVE THERAPEUTICS, INC. (As of October 1516[●], 20242026) ARTICLE I STOCKHOLDERS Section 1. The annual meeting of the stockholders of Aquestive Therapeutics, Inc. (the “Corporation”) for th... |
| 16 Oct 2026 |
Form 4: Barber Daniel, Director
Sold 25,000 shares ($106K) |
| 16 Oct 2026 |
Form 3: Daly Richard J, Director
Holds 0 shares of Common Stock |
| 15 Oct 2026 |
8-K: Regulation FD Disclosure
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 • FDA accepted the resubmission as complete and classified it as a Class 2 response • Prescription Drug User Fee Act (PDU... |
| 14 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film • Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal... |
| 07 Oct 2026 | SCHEDULE 13G |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 29 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotech... |
| 25 Sep 2026 |
8-K: Regulation FD Disclosure
Disclaimer This presentation and the accompanying oral commentary have been prepared by Aquestive Therapeutics, Inc. (“Aquestive,” the “Company,” “we,” “our” or “us”) and contain “forward-looking statements” within the meaning of the Pri... |
| 17 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
H.C. Wainwright 28th Annual Global Investment Conference September 14, 2026 |
Loading...